Samsung C&T (028260) Q3 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2024 earnings summary
10 Mar, 2026Executive summary
3Q24 sales reached KRW 10,310bn, down KRW 695bn year-over-year, with operating profit at KRW 736bn, a decrease of KRW 164bn from 3Q23.
Net profit for 3Q24 was KRW 560bn, down KRW 174bn year-over-year, with controlling interest at KRW 448bn.
Gross profit for 3Q24 was KRW 1,711bn, a decrease of KRW 202bn compared to 3Q23.
Financial highlights
Year-to-date (1-3Q) sales increased by KRW 315bn to KRW 32,111bn compared to the same period last year.
Operating profit margin for 3Q24 was 7.1%, down 1.1 percentage points year-over-year.
Non-operating profit for 3Q24 was KRW 33bn, a decrease of KRW 75bn from 3Q23.
Net cash position at 3Q24 was KRW 239bn, down from KRW 845bn at the end of 2023.
Outlook and guidance
Continued focus on hydrogen and data center projects, with new contracts and equity investments secured for future growth.
Expansion into green hydrogen and data center markets, targeting long-term partnerships and early project involvement.
Latest events from Samsung C&T
- 2Q24 delivered robust profit growth, led by Bio and F&B, amid ongoing business diversification.028260
Q2 202410 Mar 2026 - Net profit rose 15% year-over-year in 4Q 2024, driven by Bio and T&I growth.028260
Q4 202410 Mar 2026 - Net profit rose 14% year-over-year as Bio and T&I growth offset declines in other segments.028260
Q1 202510 Mar 2026 - Sequential sales and operating profit rose, but net profit fell; Bio outlook upgraded.028260
Q2 202510 Mar 2026 - Operating profit and net profit surged YoY, driven by Bio and F&B, with robust new orders.028260
Q3 202510 Mar 2026 - Net profit surged YoY in 4Q25, with Bio and E&C driving growth and a positive 2026 outlook.028260
Q4 202510 Mar 2026